Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Repare Therapeutics Inc RPTX

Healthcare Biotechnology
Repare Therapeutics Inc. is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to the discovery and development of novel therapeutics. The Company utilizes its genome-wide, CRISPR-enabled SNIPRx platform to systematically discover and develop highly targeted cancer therapies focused on genomic instability, including DNA damage repair. Its... see more

Recent & Breaking News (NDAQ:RPTX)

Repare Therapeutics Announces Portfolio Re-Prioritization, Partnering Initiatives and Cost Reductions

Business Wire 13 days ago

Repare Therapeutics Announces Positive Results of the Lunresertib and Camonsertib Combination from the MYTHIC Phase 1 Gynecologic Expansion Clinical Trial

Business Wire December 12, 2024

Repare Therapeutics to Host Webcast to Report Data from the Lunresertib and Camonsertib Combination Phase 1 MYTHIC Clinical Trial

Business Wire December 10, 2024

Repare Therapeutics Announces Agreement with the US National Cancer Institute to Advance the Development of Camonsertib

Business Wire November 12, 2024

Repare Therapeutics Provides Business and Clinical Update and Reports Third Quarter 2024 Financial Results

Business Wire November 7, 2024

Repare Therapeutics Announces Updated Positive Safety and Tolerability Results from the Phase 1 MYTHIC Clinical Trial

Business Wire October 23, 2024

Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-3467, a Polθ ATPase Inhibitor

Business Wire October 14, 2024

Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting

Business Wire September 30, 2024

Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers

Business Wire September 23, 2024

Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024

Business Wire September 13, 2024

Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio

Business Wire August 28, 2024

Repare Therapeutics to Participate in Two Upcoming Investor Conferences

Business Wire August 27, 2024

Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results

Business Wire August 6, 2024

Alberta Enterprise Corporation invests US$7.5 million into Amplitude precision medicine fund

Canada NewsWire July 16, 2024

Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI

Business Wire June 26, 2024

Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial

Business Wire June 10, 2024

Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer

Business Wire June 4, 2024

Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

Business Wire June 3, 2024

Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024

Business Wire May 29, 2024

Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results

Business Wire May 7, 2024